Adicet Bio to Present at the 2023 Jefferies London Healthcare Conference
07 Novembre 2023 - 1:00PM
Business Wire
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology
company discovering and developing allogeneic gamma delta T cell
therapies for cancer, today announced that Chen Schor, President
and Chief Executive Officer, will present at the 2023 Jefferies
London Healthcare Conference being held from November 14-16, 2023
in London.
Details of the event are as follows:
Date: Tuesday, November 14, 2023 Time: 5:00 p.m. BST
The live audio webcast of the presentation can be accessed on
the Investors section of Adicet Bio’s website at
http://www.adicetbio.com. An archived replay will be available for
30 days following the presentation.
About Adicet Bio, Inc.
Adicet Bio, Inc. is a clinical stage biotechnology company
discovering and developing allogeneic gamma delta T cell therapies
for cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma
delta T cells, engineered with chimeric antigen receptors (CARs)
and chimeric antigen adaptors (CAds), to enhance selective tumor
targeting and facilitate innate and adaptive anti-tumor immune
response for durable activity in patients. For more information,
please visit our website at https://www.adicetbio.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231107487145/en/
Adicet Bio., Inc. Investor and Media Contacts
Anne Bowdidge abowdidge@adicetbio.com
Janhavi Mohite Stern Investor Relations, Inc. 212-362-1200
janhavi.mohite@sternir.com
Adicet Bio (NASDAQ:ACET)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Adicet Bio (NASDAQ:ACET)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024